Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center
Condition(s) studied
Study summary
The aim of this study is to evaluate the oncologic and functional outcomes of RPLND as primary treatment (stage I and IIA-IIB with negative markers) or of residual masses after chemotherapy (PC-RPLND) in the treatment of patients with seminomatous and non-seminomatous.
In order to evaluate the role and the͛clinical impact of different surgical techniques of RPLND will be included patients treated with open, laparoscopic, and robot-assisted techniques
Eligibility
Primary outcome measure(s)
- Overall Survival (OS) and Recurrence-Free Survival (RFS) — through study completion, an average of 1 year
To evaluate oncological outcomes, namely Overall Survival (OS) and Recurrence-Free Survival (RFS), of O-RPLND
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna | Bologna | Recruiting |
| UO di Chirurgia Urologica della Fondazione IRCCS Istituto Nazionale dei Tumori di Milano | Milan | Italy | Recruiting |
More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06806917 on ClinicalTrials.gov ↗ ← All trials in Italy